ArticleGenes & diseases2025

Tirzepatide, a dual GIP/GLP-1 receptor agonist, alleviates metabolic dysfunction-associated steatotic liver disease by reducing the expression of CD36 and OBP2A.

Yun Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.